2 Stocks You Can’t Afford to Pass Up: Lennar Corporation (LEN), Eli Lilly and Company (LLY)

You should consider shares of Lennar Corporation (NYSE:LEN) and Eli Lilly and Company (NYSE:LLY) if you are looking for a great stocks to invest in. Starting with the LEN shares, which traded at $62.79 at the close of the recent session, gaining 1.88%. On Wednesday, the company’s shares shed $1.16 from its value which represented in intraday trading. The stock is now 12.55% higher in year-to-date (YTD) trading. LEN’s intraday high was $63.08 while its lowest price touched $61.63. The stock’s 52-week high price is $62.63, which means the current price is at 0.26%. In terms of trading activity, the daily trading volume rose to 3309389 against 200-day average trading volume of 3,198,497 shares.

What are analyst forecasts for Lennar Corporation (NYSE:LEN)?

At a consensus rating of 4.36, LEN is trending as a streaking Moderate Buy, as it has been the case a month ago when 13 analysts called it a Moderate Buy. Two months ago, 14 analysts recommended, on average, that LEN stock is a Strong Buy. The Industrial Goods company’s shares’ overall bullish trend saw it close lower on Wednesday compared to its opening price of $61.75 on the day.

Forecasts for Lennar Corporation (NYSE:LEN) give the stock a fair value for the growth of 9.0% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $69.00, which means the price per share could rise by nearly $6.21. The price range target is between a low of $62.00 and a high of $78.00. The stock would need to gain by about $19.5 to hit the estimated high or 0.69% from its 12-month low.

The consensus among 17 analysts is that it is a good time for one to Overweight in the Lennar Corporation. 11 analysts rate LEN as a Buy, with 0 of 17 analysts rate it as a Sell. 2 have valued the stock as Overweight and 4 have recommended that investors Hold.

Lennar Corporation (NYSE:LEN) Upgrades and Downgrades

In terms of rating changes, Argus on December 23, 2019, Reiterated Lennar Corporation (LEN) at Buy. They believe the stock could reach $65 in the near term. Analysts at RBC Capital Mkts have assigned a Sector Perform rating for the stock in their research note on December 17, 2019 with an estimated price target of $62. Moreover, Barclays analysts issued a rating of Overweight for the stock on October 03, 2019, giving it a price target of $63 for the next 12 months. On September 25, 2019, the stock earned a Outperform rating due to an analyst call from Raymond James, while analysts from KeyBanc Capital Markets on September 18, 2019 suggested that the stock is Sector Weight.

Eli Lilly and Company (NYSE:LLY) adds $0.46 on Wednesday

The LLY stock has risen 7.37% year-to-date and is currently trading at $141.11, which is 0.15% below its 52-week high. The company shares gained 0.33% on the day and have risen nearly 39.22% off a low hit. At current levels, Eli Lilly and Company has a valuation of about $22.64B. As of 01/15/20, this stock has risen 5.53% during the week and closed at $140.65 in the previous session. However, recent Eli Lilly and Company stock performance shows that LLY shares are 16.11% up over the last month, and 28.63% up for the last three months.

Earnings per share (EPS) estimates for the current quarter are $1.34, with the trailing 12-month share earnings at $4.64. The ratio is expected to be up by 4.90% for the current year 2019 and 16.50% for next year. Over the next 5-year period, earnings per share will be 11.80%. But will the LLY stock surprise in the current quarter results, where the $1.48 actual EPS reported on 9/29/2019 surprised by 5.70% or was higher by $0.08 from the estimated $1.4.

Sales Growth to climb 7.30% for the year

How well will Eli Lilly and Company perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $5.65B and $6.07B in current quarter sales. The consensus estimated for the current quarter is $5.9B from sales. Forecasts for this fiscal year are between $21.86B and $22.4B and the consensus estimate for sales is at $22.15B. LLY has its next quarter sales estimates at between $5.47B and $5.68B, with the quarter-over-quarter growth estimates at 9.00% and the annual growth forecast for the year at 7.30%.

Who owns shares in Eli Lilly and Company (LLY)?

Let’s briefly focus on the share ownership of the Eli Lilly and Company (NYSE:LLY) stock, where we find that 80.83% of shares are held by institutions. Lilly Endowment, Inc tops the list of institutional owners as it is holding 114.56 million shares or 11.93% of shares outstanding. Vanguard Group, Inc. (The) and Blackrock Inc. held 70.97 million and 61.15 million representing 7.39% and 6.37% respectively at the close of the last trading session. As of Sep 29, 2019, Primecap Management Company accounted for 42.83 million shares at over 4.79 billion. This represented 4.46% of shares outstanding. Wellington Management Company, LLP held 39.66 million shares at over 4.44 billion representing 4.13% of shares outstanding.

LLY Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at Eli Lilly and Company (LLY), a total of 3172452 shares have been sold by insiders over the last 6 months while 95888 shares were added in the same time span. On 1/10/2020, by the name Lilly Endowment Inc sold 210000.0 shares worth $29.0 million at the price of $138.00 per share. Filings also show that Lilly Endowment Inc sold a total of 201286.0 shares on 3/26/2019 valued at $26.4 million. Since the last insider activity, the company’s share price has climbed 7.70%.